United States Biotechnology & Medical Research

Climb Bio Inc (CLYM)

Track

Track

Climb Bio Inc experienced two insider trading transactions recently, totaling over $813,000 in sales. These divestments occurred amid a 65.3% stock price increase over the last quarter. Following a positive earnings report where the company beat expectations by 18.18%, shares are trading near their 52-week high.
Ticker: CLYM Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Climb Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Brennan Aoife President and CEO Executive Director
Transaction date
Planned sale
Price
280.23
Quantity 40,239 -42.1%
Value US$2,077,620
AOIFE BRENNAN Officer; Director Executive Director
Transaction date
Proposed sale
Price
169.25
Quantity 86,832
Value US$2,245,820
Thomas Stephen Basil Non-Executive Director
Transaction date
Planned sale
Price
406.61
Quantity 46,560 -27.8%
Value US$3,346,892
Thomas Stephen Basil Non-Executive Director
Transaction date
Planned sale
Price
7.00
Quantity 33,687 -16.5%
Value US$235,964
STEPHEN THOMAS Director Non-Executive Director
Transaction date
Proposed sale
Price
6.36
Quantity 50,000
Value US$318,000
Thomas Stephen Basil Non-Executive Director
Transaction date
Planned sale
Price
5.81
Quantity 10,000 -4.7%
Value US$58,141
Thomas Stephen Basil Non-Executive Director
Transaction date
Planned sale
Price
5.23
Quantity 90,000 -29.5%
Value US$470,988
STEPHEN THOMAS Director Non-Executive Director
Transaction date
Proposed sale
Price
5.56
Quantity 100,000
Value US$556,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
3.50
Quantity 7,111 +0.2%
Value US$24,888
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.86
Quantity 101,462 +3.1%
Value US$290,181
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
2.18
Quantity 213,099 +6.9%
Value US$464,556
Brennan Aoife President and CEO Executive Director
Transaction date
Planned sale
Price
1.22
Quantity 20,618 -30.0%
Value US$25,154
1.5
Pimblett Emily SVP, Finance & CAO Officer
Transaction date
Planned sale
Price
1.24
Quantity 1,242 -6.2%
Value US$1,540
1.5
Pimblett Emily SVP, Finance & CAO Officer
Transaction date
Planned sale
Price
1.31
Quantity 1,199 -7.3%
Value US$1,571
1.5
Pimblett Emily CHIEF ACCOUNTING OFFICER Officer
Transaction date
Planned sale
Price
2.02
Quantity 1,235 -9.8%
Value US$2,495
1.5
Pimblett Emily CHIEF ACCOUNTING OFFICER Officer
Transaction date
Planned sale
Price
8.06
Quantity 9 -0.1%
Value US$73
1.5
Pimblett Emily CHIEF ACCOUNTING OFFICER Officer
Transaction date
Planned sale
Price
8.18
Quantity 1,182 -13.5%
Value US$9,669
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.98
Quantity 30,000 -48.9%
Value US$239,400
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
8.07
Quantity 39,005 -38.9%
Value US$314,770
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.24
Quantity 50,000 -33.3%
Value US$362,000
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.09
Quantity 10,201 -6.4%
Value US$72,325
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
6.93
Quantity 38,576 -19.4%
Value US$267,332
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
6.91
Quantity 3,207 -1.6%
Value US$22,160
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.13
Quantity 50,000 -19.8%
Value US$356,500
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.01
Quantity 42,377 -14.4%
Value US$297,063
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.07
Quantity 50,000 -14.5%
Value US$353,500
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.11
Quantity 50,000 -12.7%
Value US$355,500
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
6.83
Quantity 50,000 -11.2%
Value US$341,500
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
6.66
Quantity 5,931 -1.3%
Value US$39,500
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
7.06
Quantity 12,342 -2.7%
Value US$87,135
3.5
Morisset Valerie EVP, R&D AND CSO Officer
Transaction date
Sale
Price
6.76
Quantity 50,000 -9.7%
Value US$338,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
3.84
Quantity 1,059,375 +58.6%
Value US$4,068,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
3.84
Quantity 11,949,171 +103.3%
Value US$45,884,817
1.5
Pimblett Emily CHIEF ACCOUNTING OFFICER Officer
Transaction date
Sale
Price
7.21
Quantity 1,245 -24.9%
Value US$8,982
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-30 2026-06-29 PlS Planned sale
Brennan Aoife

President and CEO

Executive Director
40,239 -42.1%
280.23
US$2,077,620 		40,239 -42.1% 280.23 US$2,077,620
2026-06-30 2026-06-29 PrS Proposed sale
AOIFE BRENNAN

Officer; Director

Executive Director
86,832
169.25
US$2,245,820 		86,832 169.25 US$2,245,820
2026-02-27 2026-02-26 PlS Planned sale
Thomas Stephen Basil
Non-Executive Director
46,560 -27.8%
406.61
US$3,346,892 		46,560 -27.8% 406.61 US$3,346,892
2026-02-27 2026-02-25 PlS Planned sale
Thomas Stephen Basil
Non-Executive Director
33,687 -16.5%
7.00
US$235,964 		33,687 -16.5% 7.00 US$235,964
2026-02-25 2026-02-25 PrS Proposed sale
STEPHEN THOMAS

Director

Non-Executive Director
50,000
6.36
US$318,000 		50,000 6.36 US$318,000
2026-02-17 2026-02-13 PlS Planned sale
Thomas Stephen Basil
Non-Executive Director
10,000 -4.7%
5.81
US$58,141 		10,000 -4.7% 5.81 US$58,141
2026-02-17 2026-02-12 PlS Planned sale
Thomas Stephen Basil
Non-Executive Director
90,000 -29.5%
5.23
US$470,988 		90,000 -29.5% 5.23 US$470,988
2026-02-12 2026-02-12 PrS Proposed sale
STEPHEN THOMAS

Director

Non-Executive Director
100,000
5.56
US$556,000 		100,000 5.56 US$556,000
2026-01-07 2026-01-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
7,111 +0.2%
3.50
US$24,888 		7,111 +0.2% 3.50 US$24,888
2025-12-15 2025-12-12 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
101,462 +3.1%
2.86
US$290,181 		101,462 +3.1% 2.86 US$290,181
2025-12-15 2025-12-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
213,099 +6.9%
2.18
US$464,556 		213,099 +6.9% 2.18 US$464,556
2025-07-01 2025-06-30 PlS Planned sale
Brennan Aoife

President and CEO

Executive Director
20,618 -30.0%
1.22
US$25,154 		20,618 -30.0% 1.22 US$25,154
2025-06-20 2025-06-20 PlS Planned sale
1.5
Pimblett Emily

SVP, Finance & CAO

Officer
1,242 -6.2%
1.24
US$1,540 		1,242 -6.2% 1.24 US$1,540
2025-03-20 2025-03-20 PlS Planned sale
1.5
Pimblett Emily

SVP, Finance & CAO

Officer
1,199 -7.3%
1.31
US$1,571 		1,199 -7.3% 1.31 US$1,571
2024-12-20 2024-12-19 PlS Planned sale
1.5
Pimblett Emily

CHIEF ACCOUNTING OFFICER

Officer
1,235 -9.8%
2.02
US$2,495 		1,235 -9.8% 2.02 US$2,495
2024-09-20 2024-09-20 PlS Planned sale
1.5
Pimblett Emily

CHIEF ACCOUNTING OFFICER

Officer
9 -0.1%
8.06
US$73 		9 -0.1% 8.06 US$73
2024-09-20 2024-09-20 PlS Planned sale
1.5
Pimblett Emily

CHIEF ACCOUNTING OFFICER

Officer
1,182 -13.5%
8.18
US$9,669 		1,182 -13.5% 8.18 US$9,669
2024-07-23 2024-07-22 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
30,000 -48.9%
7.98
US$239,400 		30,000 -48.9% 7.98 US$239,400
2024-07-23 2024-07-22 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
39,005 -38.9%
8.07
US$314,770 		39,005 -38.9% 8.07 US$314,770
2024-07-23 2024-07-19 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
50,000 -33.3%
7.24
US$362,000 		50,000 -33.3% 7.24 US$362,000
2024-07-23 2024-07-19 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
10,201 -6.4%
7.09
US$72,325 		10,201 -6.4% 7.09 US$72,325
2024-07-19 2024-07-18 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
38,576 -19.4%
6.93
US$267,332 		38,576 -19.4% 6.93 US$267,332
2024-07-19 2024-07-17 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
3,207 -1.6%
6.91
US$22,160 		3,207 -1.6% 6.91 US$22,160
2024-07-17 2024-07-16 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
50,000 -19.8%
7.13
US$356,500 		50,000 -19.8% 7.13 US$356,500
2024-07-16 2024-07-15 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
42,377 -14.4%
7.01
US$297,063 		42,377 -14.4% 7.01 US$297,063
2024-07-16 2024-07-12 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
50,000 -14.5%
7.07
US$353,500 		50,000 -14.5% 7.07 US$353,500
2024-07-11 2024-07-11 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
50,000 -12.7%
7.11
US$355,500 		50,000 -12.7% 7.11 US$355,500
2024-07-11 2024-07-10 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
50,000 -11.2%
6.83
US$341,500 		50,000 -11.2% 6.83 US$341,500
2024-07-11 2024-07-09 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
5,931 -1.3%
6.66
US$39,500 		5,931 -1.3% 6.66 US$39,500
2024-07-09 2024-07-05 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
12,342 -2.7%
7.06
US$87,135 		12,342 -2.7% 7.06 US$87,135
2024-07-03 2024-07-03 S Sale
3.5
Morisset Valerie

EVP, R&D AND CSO

Officer
50,000 -9.7%
6.76
US$338,000 		50,000 -9.7% 6.76 US$338,000
2024-07-01 2024-06-27 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,059,375 +58.6%
3.84
US$4,068,000 		1,059,375 +58.6% 3.84 US$4,068,000
2024-07-01 2024-06-27 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
11,949,171 +103.3%
3.84
US$45,884,817 		11,949,171 +103.3% 3.84 US$45,884,817
2024-06-21 2024-06-20 S Sale
1.5
Pimblett Emily

CHIEF ACCOUNTING OFFICER

Officer
1,245 -24.9%
7.21
US$8,982 		1,245 -24.9% 7.21 US$8,982
Explore more

More insider trading research around Climb Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America